Luise Klapper
Overview
Explore the profile of Luise Klapper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
VON Bernuth A, Ribbat-Idel J, Klapper L, Jagomast T, Rades D, Leichtle A, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982215
Patients with head and neck squamous cell carcinoma (HNSCC) continue to have a rather poor prognosis. Treatment-related comorbidities have negative impacts on their quality of life. TRIM21 is a cytosolic...
2.
Dressler F, Dabadghao D, Klapper L, Perner S, Idel C, Ribbat-Idel J
Virchows Arch
. 2022 Jul;
481(3):453.
PMID: 35900585
No abstract available.
3.
Dressler F, Dabadghao D, Klapper L, Perner S, Idel C, Ribbat-Idel J
Virchows Arch
. 2022 Jul;
481(3):443-451.
PMID: 35779078
Immunohistochemical (IHC) predictive quantitation of PDL1 expression is obligatory in many cancer entities with improved response to immune checkpoint inhibition in PDL1-positive subgroups. With recent demonstration of increased positivity rates...
4.
Klapper L, Idel C, Kuppler P, Jagomast T, VON Bernuth A, Bruchhage K, et al.
J Pers Med
. 2022 Jun;
12(6).
PMID: 35743773
Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most common cancers in humans worldwide and have a rather poor prognosis. TRIM24 has various intracellular functions and was...
5.
Bottner J, Ribbat-Idel J, Klapper L, Jagomast T, Lemster A, Perner S, et al.
Int J Mol Sci
. 2022 May;
23(9).
PMID: 35563463
Head and neck squamous cell carcinomas (HNSCC) are among the most common cancers worldwide and are associated with a poor prognosis for patients. Among HNSCC, those originating in the hypopharynx...
6.
Jagomast T, Idel C, Klapper L, Kuppler P, Offermann A, Dreyer E, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158760
HNSCC is the sixth most common cancer worldwide and the prognosis is still poor. Here, we investigated the prognostic implications of CDK7 and pMED1. Both proteins affect transcription, and their...
7.
Idel C, Ribbat-Idel J, Klapper L, Krupar R, Bruchhage K, Dreyer E, et al.
Front Oncol
. 2021 Nov;
11:712788.
PMID: 34778030
Background: Head and neck squamous cell carcinomas (HNSCCs) have a very moderate response rate to immune checkpoint inhibitor (ICI) treatment compared to other cancer types. Lacking predictive markers for treatment...
8.
Ribbat-Idel J, Dressler F, Krupar R, Watermann C, Paulsen F, Kuppler P, et al.
Front Med (Lausanne)
. 2021 May;
8:640515.
PMID: 33987192
The approval of immune checkpoint inhibitors in combination with specific diagnostic biomarkers presents new challenges to pathologists as tumor tissue needs to be tested for expression of programmed death-ligand 1...
9.
Ribbat-Idel J, Perner S, Kuppler P, Klapper L, Krupar R, Watermann C, et al.
Front Med (Lausanne)
. 2021 Feb;
8:622330.
PMID: 33585526
Head and neck squamous cell carcinoma (HNSCC) represents a common cancer worldwide. Past therapeutic advances have not significantly improved HNSCC prognosis. Therefore, it is necessary to further stratify HNSCC, especially...
10.
Klapper L, Ribbat-Idel J, Kuppler P, Paulsen F, Bruchhage K, Rades D, et al.
Int J Mol Sci
. 2020 Aug;
21(15).
PMID: 32752295
Head and neck squamous cell carcinoma (HNSCC)is the 6th most common cancer in humans worldwide and is associated with a poor prognosis for patients. NR2F6 has been identified as an...